Figure 1. Summary of the data available for analysis.

A) Mean ± SEM of sirolimus trough levels are indicated at each time points for CYP3A5 expressors and non-expressors. Dashed lines indicate the target values. B) Flowchart of SIRILYGRE study summarizing data available for analysis. Among the 4 patients (Pt) excluded because of sirolimus discontinuation, 2 (#25 & #27, in bold) experienced severe inflammatory symptoms. Five sera were excluded from analysis because of the presence of a documented confounding inflammatory condition (sepsis). For one patient (#11) no analysis of cytokine dosage could be performed because time point of collection was not indicated on the tubes.